Stocks Comparison
Cencora vs Cellyan Biotechnology: revenue, profit, margins and growth compared
Cencora brought in $321.3B of revenue in fiscal 2025, Cellyan Biotechnology $20.3M in fiscal 2025. Revenue changed by +9.3% at Cencora and +21.7% at Cellyan Biotechnology on the year before, so Cellyan Biotechnology grew faster. Cencora kept 0.5% of its revenue as net profit, Cellyan Biotechnology -0.1%. Free cash flow was $3.2B at Cencora and $499.3K at Cellyan Biotechnology.
Side by side, latest fiscal year
| COR | HKPD | |
|---|---|---|
| Fiscal year ended | FY2025 (September 30, 2025) | FY2025 (March 31, 2025) |
| Revenue | $321.3B | $20.3M |
| Revenue growth | +9.3% | +21.7% |
| Net income | $1.6B | -$27.1K |
| Net margin | 0.5% | -0.1% |
| Free cash flow | $3.2B | $499.3K |
| Free cash flow margin | 1.0% | 2.5% |
| Earnings per share (diluted) | $7.96 | -$0.00 |
| Cash | $4.4B | $748.7K |
| Debt | $7.7B | $1.9M |
| Price to earnings | 38.6 | n/a |
| Market value | $58.6B | $5.4M |
| Dividend yield | 0.72% | n/a |
| Rank by revenue in sector | #3 of 646 · Health care | #434 of 646 · Health care |
Over the years
Questions about Cencora and Cellyan Biotechnology
Which is bigger by revenue, Cencora or Cellyan Biotechnology?
Cencora is bigger by revenue: $321.3B in fiscal 2025, against $20.3M for Cellyan Biotechnology in fiscal 2025.
Which keeps more of its revenue as profit, Cencora or Cellyan Biotechnology?
Cencora had a net margin of 0.5% in fiscal 2025; Cellyan Biotechnology had -0.1% in fiscal 2025.
Which grew revenue faster, Cencora or Cellyan Biotechnology?
In their latest fiscal years revenue changed by +9.3% at Cencora and +21.7% at Cellyan Biotechnology.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.